AnSong Medical Completes CNY 100 Million Series C Funding Round Led by SAIF Partners to Advance Domestic Ceramic Joint Solutions

VCBeat learned第一时间 that Arthrone Co., Ltd. (referred to as "Arthrone") announced the completion of a CNY 100 million Series C financing round. This round was led by SAIF Partners, with participation from CDIB Venture Capital and others. The funds will be used to accelerate the sales rollout of ceramic joint products and the research and development of subsequent product pipelines.

Arthrone Co., Ltd., established in 2017, is the only joint enterprise in China that simultaneously masters the production technology of two ceramic materials, zirconia and alumina. Its zirconia ceramic ball head has officially entered the special approval process for innovative medical devices by the National Medical Products Administration, fundamentally breaking the technical monopoly of foreign manufacturers, filling the market gap, and leading new international technical standards. As a materials and device integrated R&D and manufacturing enterprise, the company has undertaken the "challenge-list leadership" innovation task for zirconia biomedical materials jointly issued by the Ministry of Industry and Information Technology and the National Medical Products Administration, committing to solving "bottleneck" problems and accelerating the localization substitution of the entire industry chain.

In the global orthopedic market, artificial joints account for nearly 40% of the share, making it the largest细分市场 for orthopedic implants. Among these, ceramic heads, as a core cost component of artificial joints, still rely on a single境外 supplier. Imported ceramic heads remain in an absolute monopoly position, and the development path for domestically produced joint instruments remains long and challenging.

Mr. Zhang Jifeng, Chairman of Arthrone Co., Ltd.After the national volume-based procurement in the artificial joint industry, the usage proportion of ceramic femoral heads for hip joint prostheses has increased to 90%. However, all ceramic femoral heads in China are supplied by a single overseas supplier, posing significant industry risks to the life safety of domestic patients. The core product of Arthrone, zirconia ceramic joints, achieves self-research and self-production of ceramic femoral heads, breaking the monopoly of foreign imports. Unique patented technology and strict production quality control processes make the product performance comprehensively superior to imported products, with significant cost advantages, providing Chinese patients with high-quality domestically produced ceramic joints at a better price-performance ratio. In the future, Arthrone will continue to adhere to original innovation, taking solving "bottleneck" problems and breaking "imported technology blockades" as its mission, continuously contributing to the localization of medical device materials, and enabling China's own ceramic joints to benefit society as soon as possible.

Mr. Chen Zeyi from SAIF PartnersAs China enters an aging society, the impact of joint health on the quality of life of middle-aged and elderly people is gradually gaining attention. Arthrone Co., Ltd. continues to strive for excellence and has mastered globally leading research, development, and manufacturing technology for medical zirconia, with several performance indicators far exceeding FDA industry standards. The upcoming launch of Arthrone’s zirconia joint heads will break foreign monopolies and achieve domestic substitution of core components. SaiFu is honored to participate in this round of investment, supporting Arthrone Co., Ltd. in providing safe and effective product technologies for patients with joint injuries.

Mr. Liu Bo from CDIB Venture CapitalAs China's aging population gradually intensifies, the volume of artificial joint surgeries is rapidly increasing, indicating significant growth potential for the future artificial joint market. After over two decades of deep accumulation by multiple teams, Arthrone has overcome and mastered the scarce upstream technology of ceramic artificial hip joints, breaking the technical monopoly of foreign manufacturers. With its self-developed cutting-edge ceramic material technology, Arthrone is well-positioned to seize the crucial opportunities brought by the transformation in the artificial joint industry amid the normalization of national centralized procurement. It is expected to become a leading enterprise in the localization of the entire ceramic joint industry chain.

SAIF Partners, founded in 2001, is a private equity fund management company focused on investments in growth-stage and early-stage high-tech enterprises. It is one of the earliest large-scale equity investment fund management platforms in China. SAIF currently manages funds with a total scale of nearly 70 billion RMB, investing in and managing nearly 400 enterprises, including more than 80 listed companies both domestically and overseas.

CDIB Venture Capital, as a key member of CDIB Capital Group, boasts extensive industry experience and abundant group resources. By employing diversified investment strategies, it achieves superior risk-adjusted returns on investments. Currently managing assets worth $23 billion, its investment portfolio includes over 200 companies. CDIB Venture Capital provides professional advisory services through its expert investment team and customized private equity fund investment programs. It also builds a closely integrated global corporate network, offering clients comprehensive financial services with unlimited reach. Focusing on raising and managing equity investment funds, CDIB Venture Capital actively expands its asset management business, playing a pivotal leadership role in the venture capital and private equity markets.